Reducing liver cancer risk in people with chronic hepatitis B — Zhiyuan Project

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective, observational real-world study collecting treatment and outcome data from adults with chronic hepatitis B across hospitals in China. Participants receiving commonly used antivirals (entecavir, TDF, TAF, TMF) or pegylated interferon α-2b will be followed under usual-care conditions to compare outcomes such as viral suppression, liver function, hepatocellular carcinoma development, and markers related to functional cure. Patients with decompensated cirrhosis, existing hepatocellular carcinoma, or concurrent participation in other interventional trials are excluded, and written informed consent is required. The study aims to analyze real-world treatment patterns and long-term outcomes to inform optimized treatment and follow-up strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1.Chronic HBV infection (HBsAg-positive for ≥6 months); 2.Age ≥18 years; 3.Patients who, based on real-world clinical practice needs, are planned or currently receiving treatment with:Entecavir (ETV),Tenofovir disoproxil fumarate (TDF),Tenofovir alafenamide fumarate (TAF),Tenofovir amibufenamide (TMF) OR Pegylated interferon α-2b-naïve patients OR Patients re-initiating pegylated interferon α-2b therapy; 4.Written informed consent obtained from the patient.

Exclusion Criteria:

* 1.Severe hepatic dysfunction or decompensated cirrhosis; 2.Concurrent participation in other clinical trials; 3.Hepatocellular carcinoma (HCC).

Where it's running

• Huaxian People's Hospital
  Anyang, China Recruiting
• Linzhou City People's Hospital
  Anyang, China Recruiting
• Neihuang County People's Hospital
  Anyang, China Recruiting
• Tangyin County People's Hospital
  Anyang, China Recruiting
• The Fifth People's Hospital of Anyang
  Anyang, China Recruiting
• The First Affiliated Hospital of Xinxiang Medical University (Hua County Branch)
  Anyang, China Recruiting

+112 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Hongxia Liang — The First Affiliated Hospital of Zhengzhou University
• Study coordinator: Hongxia Liang
• Email: hxliang@zzu.edu.cn
• Phone: 18595871806

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of functional cure on patient-reported outcomes in chronic hepatitis B

  This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou · NCT07855029

• Sequential combination therapy for functional cure of chronic hepatitis B

  This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.

  Recruiting Phase 2 The Second Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07852091

• Combination therapy for functional cure in chronic hepatitis B

  This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.

  Recruiting Phase 2 The Second Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07845058

• GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B

  A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.

  Recruiting Phase 2 Fujian Akeylink Biotechnology Co., Ltd. · Beijing · NCT07709520

• AHB-137 injection in people with chronic hepatitis B

  This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.

  Recruiting at 34 sites Phase 2 Ausper Biopharma Co., Ltd. · Beijing, Beijing Municipality and 33 other locations · NCT07635186

• AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function

  This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.

  Recruiting Phase 1 Ausper Biopharma Co., Ltd. · Chongqing, Chongqing Municipality and 4 other locations · NCT07600788

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.